R ecent advances in our understanding of the events leading to T-cell activation allow the development of novel approaches to immunotherapy. Recent strategies to augment the immune response of the host to tumors have included the introduction of genes encoding major histocompatibility complex (MHC) antigens (Ags), costimulatory molecules, or cytokines into tumor cells. [1] [2] [3] [4] The goal of these approaches is to improve the immunogenicity and the Ag-presenting capability of tumor cells. Gene-modified tumor vaccines were shown to be capable of eliciting T-cell-mediated antitumoral responses in several animal tumor models. However, the clinical use of these approaches may be hindered if the defects in signaling are variable for individual tumors and patients.
In the past several years, dendritic cells have been identified as the most effective Ag-presenting cells (APCs) for the induction of a cytotoxic T-lymphocyte (CTL) response because of high expression of MHC Ags, costimulatory molecules, and their ability to produce cytokines. 5 In addition, many human tumor Ags recognized by autologous T cells have now been identified 6, 7 and were used to induce Ag-specific CD8 ϩ CTL responses. 8 Recent reports have shown that immunization using dendritic cells pulsed with purified tumorassociated peptides or proteins is a powerful method of priming CTLs and inducing host protective and therapeutic antitumoral immunity in mice and humans. 9 -11 As an alternative way of inducing CTL responses against a variety of Ags, we investigate here whether fibroblasts can be genetically modified to efficient APCs. We chose fibroblasts because they have several advantages. Fibroblasts are readily available to culture, transfect, and select, and can produce physiologically relevant levels of cytokine after transfection. [12] [13] [14] Furthermore, engineered nontumorigenic cells capable of direct priming of CTLs may prove useful by allowing manipulation of key aspects of Ag presentation such as epitope choice, Ag density, and selection of cytokines and costimulatory molecules, to favor the induction of potent CTL responses.
In this study, cDNAs for B7.1 and interleukin-2 (IL-2) molecules were transfected into BLK fibroblasts to efficiently induce a CTL response. It is now well known that B7.1 costimulation is necessary for the generation of CTLs, 15 and IL-2 plays an important role in the proliferation of CTLs and other antitumoral effector cell types such as natural killer (NK) cells. 16 In addition, IL-2 secretion by gene-transfected tumor cells themselves compensated for T helper cells in the induction of an antitumoral CTL response. 17 In this report, we have demonstrated that a strong Ag-specific antitumoral response was induced in C57BL/6 mice (H-2 b ) immunized with ovalbumin (OVA) epitope-pulsed BLK fibroblasts that combined both the secretion of IL-2 and the expression of B7.1 (BLK/IL2/B7.1/OVA). The survival of mice injected with the double-transfected BLK/IL2/B7.1/OVA cells was significantly longer than that of mice injected with the single-transfected BLK/IL2/OVA or BLK/B7.1/ OVA cells. CD8
ϩ T cells were a major effector cell type involved in the antitumoral responses enhanced by the double-transfected BLK/IL2/B7.1/OVA cells.
MATERIALS AND METHODS

Mice and cell lines
Female 7-to 9-week-old C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, Me). IL-2-dependent CTLL-2 cells (American Type Culture Collection (ATCC), Manassas, Va) were cultured in RPMI 1640 (Life Technologies, Grand Island, NY) containing fetal bovine sera (FBS) (Hyclone, Logan, Utah), 2 mM glutamate, 0.5 mM sodium pyruvate, 15 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, 5 ϫ 10 Ϫ2 mM ␤-mercaptoethanol, and 100 U/mL IL-2. BLK cells, EL4 cells, and C1498 cells were obtained from ATCC. B16F1 cells were originally obtained from Dr. I. J. Fidler (MD Anderson Cancer Center, Houston, Tex) and EG7 cells (OVA-expressing EL4 cells) were a gift of Dr. M. Bevan (University of Washington, Seattle, Wash). All cultures of tumor cells and spleen cells from C57BL/6 mice were maintained in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% FBS (growth medium).
Construction of IL-2-secreting BLK cells expressing costimulatory B7.1 (BLK/IL2/B7.1) Murine IL-2 or B7.1 cDNA was subcloned into a retroviral vector, pZipNeoSV(X) (originally from Dr. R. Mulligan, Whitehead Institute for Biomedical Research, Cambridge, Mass) (known as pZipNeoSV-IL-2 and pZipNeoSV-B7.1, respectively). The pZipNeoSV(X) vector contains the bacterial neomycin phosphotransferase gene under the control of the Moloney leukemia virus long terminal repeat. BLK fibroblasts were cotransfected with pZipNeoSV-IL-2 and pZipNeoSV-B7.1 using a cationic lipofectin-mediated transfection method (Life Technologies). To obtain stable transfected clones, transfected cells were grown in growth medium containing G418 (500 g/mL) for 14 days, and resistant clones propagated separately. Control BLK cells containing only the neomycin phosphotransferase gene were prepared by transfection with pZipNeoSV(X) using the same procedure.
Cultured cells from 56 G418-resistant clones were analyzed for IL-2 secretion and B7.1 expression as described below. Among these clones, clones 5, 11, and 46 were chosen for use in the experiments because of their much higher expression of IL-2 and/or B7.1 compared with the other clones. The measured activity in a CTLL-2 proliferation assay could be inhibited by a neutralizing anti-mouse IL-2 monoclonal antibody (mAb) (S4B6, rat immunoglobulin G2a (IgG2a)) but not by a control isotype mAb (anti-mouse IL-3, rat IgG2a), suggesting that the activity was IL-2 specific. These IL-2-secreting clones (BLK/IL2 and BLK/IL2/B7.1 cells) were used in all experiments, and culture supernatants of the cells were harvested at the time of in vivo use in every experiment to confirm the expression of IL-2. The BLK cells transfected with pZipNeoSV(X) as a control vector (BLK/ZipNeo cells) did not form detectable amounts of IL-2.
Preparation of OVA epitope-pulsed fibroblasts
The genetically engineered fibroblasts were treated with a mild acidic buffer to give large amounts of empty MHC molecules. The acid-treated fibroblasts were then pulsed with an OVA epitope (amino acids 257-264, SIINFEKL, H-2K b -restricted) (synthesized using a Synergy Peptide Synthesizer; Applied Biosystems, Foster City, Calif) as described previously. 18 In brief, fibroblasts (5 ϫ 10 6 ) were washed twice with 1% bovine serum albumin (BSA)-0.9% NaCl and resuspended in 2 mL of cold citrate-phosphate buffer (0.13 M citric acid and 0.06 M sodium phosphate, pH 3.0) containing 1% BSA and 6 g/mL ␤ 2 -microglobulin. After a 2-minute incubation on ice, 5 volumes of cold 0.15 M sodium phosphate (pH 7.5) containing 1% BSA, 6 g/mL ␤ 2 -microglobulin, and 30 g/mL OVA peptide were added, and cells were harvested by centrifugation.
IL-2 bioassay
The biological activity of IL-2 secreted from the genetically engineered fibroblasts was determined by the ability to stimulate the proliferation of IL-2-dependent CTLL-2 cells in a [ 3 H]thymidine incorporation assay as described previously. 19 Recombinant mouse IL-2 was used as a standard. One unit of IL-2 gave half-maximal proliferation of the cells under this condition.
Spleen cell-mediated cytotoxicity
Spleen cells were obtained from the spleens of C57BL/6 mice immunized with 5 ϫ 10 6 50 Gy-irradiated cells of each cell type. The cell suspensions were restimulated in vitro with mitomycin C-treated EG7 cells at 37°C for 5 days (ratio of spleen cells to EG7 cells ϭ 30:1). For mitomycin C treatment, the cells were incubated at 37°C in growth medium containing 50 g/mL mitomycin C (Sigma, St. Louis, Mo) and were then washed three times with Dulbecco's modified Eagle's medium. After restimulation in vitro, the population that failed to adhere to the plastic cell culture flasks was collected and used as effector cells for cytotoxic determinations against tumor cells. Spleen cell-mediated cytotoxic activity was measured in a standard 4-hour 51 Cr release assay as described previously. 20 The spontaneous release of isotope was determined by measuring the radioactivity released from an equivalent number of 51 Cr-labeled tumor cells during a 4-hour period of incubation at 37°C. In vitro depletion of T-cell subsets, NK cells, and macrophages mAbs for T-cell subsets and NK cells were used to identify the cell types activated for anti-OVA cytotoxicity after immunization with the various cell constructs as described previously. 21 Briefly, mononuclear cells were prepared from the spleens of C57BL/6 mice that had been immunized subcutaneously (s.c.) and intraperitoneally (i.p.), respectively, with 5 ϫ 10 6 50 Gy-irradiated cells of each cell type. The cells were restimulated in vitro with mitomycin C-treated EG7 cells for 5 days, and the nonadherent cells were collected and incubated at 4°C for 1 hour with anti-CD4 (L3T4) (hybridoma GK1.5, IgG2b), anti-CD8 (Lyt-2.2) (hybridoma 3.155, IgM) or anti-NK (NK1.1) (hybridoma PK136, IgG2a) mAbs followed by the addition of low-toxicity rabbit complement (Pel Freeze, Rogers, Ark) and further incubation at 37°C for 45 minutes. The antibodies (Abs) were titrated such that the concentrations used were five times the minimal amount required to saturate the specific binding sites of spleen cells from naive C57BL/6 mice, as determined by cytofluorometric analysis of serially diluted Abs. After the depletion of specific cell types in the spleen cell populations, cytotoxic activities were determined in a 4-hour 51 Cr release assay against tumor cells at various effector to target (E:T) ratios. Immunofluorescent analysis of the spleen cells after mAb treatment indicated that there was Ͼ98% depletion of the specific T-cell subsets with no decrease in the frequency of the other subsets.
To investigate the cell types in the induction of anti-OVA cytotoxic responses, specific cell types in spleen cells from naive mice were depleted with mAb and complement (for T cells and NK1.1 ϩ cells) or with 10 nM L-leucine methyl ester (Leu-OMe) (Sigma) for macrophages, as described previously. 22 Afterward, the depleted spleen cells were stimulated in vitro with mitomycin C-treated cell constructs (50 g/mL, 45 minutes at 37°C) for 6 days, and cytotoxic activity was determined against EG7 cells. Staining for nonspecific esterase was used to determine the proportion of remaining macrophages. 23 Immunoprotection C57BL/6 mice (10 per group) were immunized s.c. and i.p., respectively, with 5 ϫ 10 6 50 Gy-irradiated cells of each cell type. After 2 weeks, the mice were injected with 1 ϫ 10 6 EG7 cells, and the survival period of the mice was measured. For in vivo Ab depletion experiments, the treatment with mAbs started 1 week before immunizations. The mice received an excess of each mAb every other day during the 6-day period and one time per week thereafter. The efficiency and effectiveness of depletion were confirmed by cytofluorometric analysis as described below. The mean survival time Ϯ SD of tumorbearing mice in each group was determined by life-table methods and by log-rank analysis. 24 
In vivo depletion of T-cell subsets
Specific lymphocyte subsets were depleted in vivo by mAbs as described previously. 21 Ab-rich ascitic fluid was recovered from BALB/c nu/nu mice (Harlan Sprague-Dawley, Indianapolis, Ind) that had been injected previously with the relevant hybridoma cells expressing mAb. A total of 0.6 mg of anti-CD4 (L3T4), 0.5 mg of anti-CD8 (Lyt-2.2), or 0.5 mg of anti-NK1.1 mAb was administrated at each injection per mouse. Depletion of T-cell subsets was assessed on the day of immunization by cytofluorometric analysis of spleen cells stained with fluorescein isothiocyanate (FITC)-conjugated anti-L3T4, anti-Lyt-2.2, or anti-NK1.1 mAb (Becton Dickinson, Mountain View, Calif), respectively. For each depletion, Ͼ97% depletion of the appropriate subset was achieved while maintaining normal levels of the other subsets. Depletion of NK1.1 cells was determined by cytotoxicity against NK-sensitive YAC-1 targets in a standard 4-hour 51 Cr release assay.
Immunofluorescent staining and cytofluorometric measurements
Quantitative immunofluorescence measurements were performed in an Epic V flow cytofluorograph (Coulter Electronics, Hialeah, Fla) equipped with a multiparameter data acquisition and display system. Briefly, a single cell suspension was prepared from the various cultures with 0.1 mM ethylenediaminetetraacetic acid in phosphate-buffered saline (PBS) (pH 7.4). The cells were washed with PBS containing 0.02% sodium azide and 0.5% FBS. Afterward, anti-B7.1 mAb (PharMingen, San Diego, Calif) was added, followed by incubation at 4°C for 1 hour. After incubation, the cells were washed and incubated with FITC-conjugated goat anti-mouse IgG for 1 hour at 4°C and subsequently washed again with PBS containing 0.5% FBS and 0.02% sodium azide. Background staining was determined by substituting cells stained with FITC-conjugated goat antimouse IgG alone for cells stained with the specific Abs. One parameter fluorescence histogram was generated by analyzing at least 1 ϫ 10 4 cells.
Statistical analyses
Life-table methods and log-rank analyses were used to determine the statistical differences between the survival periods of mice after immunizations with the various cell constructs. The Student's t test was used to determine the statistical differences in cytotoxic activity between various experimental and control groups. A value of P Ͻ .05 was considered significant.
RESULTS
Characterization of OVA epitope-pulsed mouse fibroblasts transfected with cDNAs for IL-2 and B7.1 molecules The multistep approach described in Materials and Methods was used to construct OVA epitope-pulsed BLK fibroblasts that combined IL-2 secretion and B7.1 expression. As controls, mouse fibroblasts were modified to express one or two of three factors (IL-2, B7.1, and OVA), respectively. The IL-2-dependent CTLL-2 cell line was used to measure IL-2 activity in medium conditioned by the genetically modified cells. As indicated (Table 1) Approximately equivalent quantities of IL-2 were formed after in vitro continuous passage for Ͼ2 months, suggesting that IL-2 secretion by the IL-2-secreting fibroblasts was stable.
To investigate the expression of a costimulatory B7.1 molecule by the genetically engineered fibroblasts, the cell constructs were immunostained with anti-B7.1 mAb, followed by addition of FITC anti-mouse IgG, and analyzed by quantitative cytofluorometry. As indicated (Fig 1) , the expression of B7.1 by the BLK cells transfected with pZipNeoSV-B7.1 was significantly higher than that of BLK cells transfected with pZipNeoSV(X). The expression levels were not different between BLK/IL2/B7.1 and BLK/B7.1 cells, suggesting that the IL-2 secreted from the BLK cells transfected with pZipNeoSV-IL-2 had no significant effect on the expression of a B7.1 molecule by the transfected cells. In addition, the parental BLK cells and transfected BLK cells significantly expressed H-2K b Ag, and the expression levels were not significantly different between the parental and transfected cells (data not shown).
Immunization with BLK/IL2/B7.1/OVA cells induced the highest anti-OVA cytotoxic response compared with any other cell constructs To investigate whether the BLK/IL2/B7.1/OVA cells induce a cellular anti-OVA immune response, the C57BL/6 mice were injected s.c. and i.p., respectively, with 5 ϫ 10 6 BLK/IL2/B7.1/OVA cells. As controls, the mice were injected with one of the other cell constructs (BLK/IL2/B7.1, BLK/IL2/OVA, BLK/B7.1/OVA, BLK/ IL2, BLK/B7.1, BLK/OVA, or BLK/ZipNeo cells), or the mice were not injected. The mice were sacrificed 2 weeks later, and spleen cell-mediated cytotoxic activities were determined in a 51 Cr release assay. As shown (Fig  2A) , immunization with the BLK/IL2/B7.1/OVA cells induced the highest spleen cell-mediated cytotoxicity against OVA-expressing EL4 (EG7) cells compared with 6 cells of each type; after 2 weeks, spleen cell-mediated cytotoxic activities were determined in a 4-hour 51 Cr release assay against OVA-expressing EL4 (EG7) cells (E:T ratio of 100:1). ‫,ء‬ P Ͻ 0.005, relative to any other groups. B: Mice were immunized with the BLK/IL2/B7.1/OVA cells, and spleen cell-mediated cytotoxic activities were determined against EL4, EG7, C1498, or B16F1 tumor cells (E:T ratio of 100:1). The numbers represent the mean Ϯ SD of triplicate determinations. The experiment was repeated twice with similar results. ‫,ء‬ P Ͻ 0.001, relative to any other groups. (Fig 2B) . Thus, immunization with a cell construct that combined IL-2 secretion and B7.1 expression led to heightened cellular anti-OVA immune responses.
CD8
ϩ T cells were a major effector cell type augmented by the double-transfected BLK/IL2/B7.1/OVA cells To determine the cell type(s) activated for the anti-OVA immune response in mice immunized with the genetically engineered BLK cells, spleen cell populations from the immunized C57BL/6 mice were treated with excess amounts of mAbs (anti-CD8, anti-CD4, or anti-NK1.1 mAbs) and complement before the determination of cytotoxic activity toward 51 Cr-labeled EG7 cells, as described in the Materials and Methods.
As indicated (Table 2) , treatment with anti-CD8 mAb significantly reduced the spleen cell-mediated anti-OVA cytotoxicities in mice injected with the BLK/IL2/B7.1/ OVA cells, BLK/B7.1/OVA cells, or BLK/OVA cells. Under similar conditions, the anti-CD4 mAb had no effect. As shown previously, the double-transfected BLK/IL2/B7.1/OVA cells generated the highest anti-OVA cytotoxic responses.
The effect of anti-NK1.1 mAb on the effector stage of the anti-OVA response in mice immunized with the various cell constructs was investigated as well. The cytotoxic response in mice injected with BLK/IL2/B7.1 or BLK/IL2 cells was significantly inhibited by anti-NK1.1 mAb. In contrast, anti-NK1.1 mAb did not affect the cytotoxic response in mice immunized with the BLK/OVA or BLK/B7.1/OVA cells. The antitumoral response after immunization with the BLK/IL2/B7.1/ OVA cells was only partially inhibited by anti-NK1.1 mAb.
Thus, CD8 ϩ cells were a major effector cell type in mice immunized with the BLK cells pulsed with an OVA peptide (BLK/IL2/B7.1/OVA, BLK/IL2/OVA, BLK/ B7.1/OVA, and BLK/OVA), and NK1.1 ϩ cells were predominant in mice immunized with IL-2-secreting BLK cells, which were not pulsed with an OVA peptide (BLK/IL2/B7.1 and BLK/IL2).
Immunization with BLK/IL2/B7.1/OVA cells significantly prolonged the survival of mice injected with OVA-expressing EL4 tumor cells The immunoprotective properties of the BLK/IL2/B7.1/ OVA cells toward the growth of EG7 cells in C57BL/6 mice were determined. As indicated (Fig 3) , mice receiving the BLK/IL2/B7.1/OVA cells followed by an injection of EG7 cells 2 weeks later survived significantly longer than nonimmunized mice or mice immunized with the BLK/ZipNeo cells (P Ͻ .001). The BLK/B7.1 and BLK/OVA cells, like BLK/ZipNeo cells, were not protective.
As in the in vitro studies described previously, the importance of IL-2 secretion and B7.1 expression was again apparent. Mice injected with BLK/IL2/OVA, BLK/B7.1/OVA, or BLK/IL2 cells survived longer after tumor challenge than mice injected with BLK/ZipNeo cells (P Ͻ .05). However, the period of survival was significantly shorter than that for mice immunized with the BLK/IL2/B7.1/OVA cells (P Ͻ .01). 
*C57BL/6 mice (three mice per group) were immunized s.c. and i.p., respectively, with 5 ϫ 10 6 cells of each cell type. After 2 weeks, spleen cell populations were restimulated in vitro, and specific cell types were depleted using mAbs and complement, or not depleted (Ϫ) before cytotoxic activities were determined against 51 Cr-labeled EG7 cells. Values represent the mean Ϯ SD of triplicate determinations. The experiment was repeated twice with similar results.
†P Ͻ .05, relative to (Ϫ) (not depleted) of each group. ‡Not determined.
Thus, the combination of B7.1 expression and IL-2 secretion led to the highest level of immunity toward the EG7 cells in both in vitro and in vivo tests of tumor immunity.
Induction of antitumoral CTL immunity by BLK/IL2/ B7.1/OVA cells was independent of host APCs, CD4 ϩ cells, and NK1.1 ϩ cells
To determine the cell type(s) required for the induction of the anti-OVA response, spleen cell populations from naive C57BL/6 mice were depleted with mAbs and complement (for T cells and NK1.1 ϩ cells) or with 10 nM Leu-OMe (for macrophages) before in vitro stimulation with the BLK/IL2/B7.1/OVA cells or BLK/ ZipNeo cells.
As shown (Fig 4) , anti-OVA cytotoxic responses developed in spleen cells from naive mice during a 6-day period of coincubation with mitomycin C-treated BLK/ IL2/B7.1/OVA cells. Under similar conditions, the responses failed to develop if the spleen cells were incubated alone or with the BLK/ZipNeo cells. Pretreatment of the spleen cells with anti-CD4 mAb, anti-NK1.1 mAb, or Leu-OMe before the addition of the BLK/IL2/B7.1/ OVA cells did not affect the generation of the anti-OVA cytotoxic response. In contrast, depletion of CD8 ϩ cells before the addition of the BLK/IL2/B7.1/OVA cells significantly reduced the anti-OVA cytotoxic response (P Ͻ .01), suggesting that the BLK/IL2/B7.1/OVA cells directly induced an Ag-specific, CD8
ϩ CTL response independent of host APCs, CD4 ϩ cells, and NK1.1 with EG7 cells or were sacrificed for in vitro restimulation of spleen cells and subsequent cytotoxic assays. The mAb treatment started 1 week before the immunization, and the mice received an excess of each mAb every other day during the 6-day period and then once per week. As shown (Fig 5A) , the survival period of mice injected with anti-CD8 (Lyt-2.2) mAb followed by immunization with the BLK/IL2/B7.1/OVA cells was significantly less than that for mice injected with the BLK/IL2/B7.1/OVA cells alone (P Ͻ .001). In contrast, treatment with anti-CD4 (L3T4) mAb or anti-NK1.1 mAb did not reduce the protective effect of the BLK/IL2/B7.1/OVA cells on the growth of EG7 cells. The result indicates that induction of the tumor-protective effect by BLK/IL2/B7.1/OVA immunization is wholly dependent upon CD8 ϩ T cells and not on CD4 ϩ and NK1.1 ϩ cells. Analysis of the CTL activity after in vitro restimulation of spleen cells from the various depleted, immunized mice confirmed the results obtained in the tumor challenge experiment, in that CD4-and NK1.1-depleted mice were still capable of inducing an anti-OVA CTL response in response to immunization with the BLK/ IL2/B7.1/OVA cells (Fig 5B) .
Thus, immunization with BLK/IL2/B7.1/OVA cells can directly induce an Ag-specific, CD8
ϩ CTL response independent of host APCs and CD4 ϩ and NK1.1 ϩ cells.
DISCUSSION
The main emphasis of this study was to construct genetically engineered APCs using fibroblasts and to (Fig  3) . Furthermore, the double-transfected BLK/IL2/B7.1/ OVA cells induced higher cellular cytotoxic responses against OVA-expressing EL4 tumors than the singletransfected BLK/IL2/OVA or BLK/B7.1/OVA cells (Fig  2) . The major effector cell type was CD8 ϩ (Lyt-2.2) T (Table 2 ). In contrast, NK1.1 ϩ cells were a major effector cell type in mice injected with IL-2-secreting fibroblasts that were not pulsed with an OVA peptide (BLK/IL2/B7.1 and BLK/IL2 cells), suggesting that the pulsed OVA epitope gave OVA specificity to genetically engineered fibroblasts to induce an OVAspecific antitumoral response. These results suggest that all three factors (IL-2, B7.1, and OVA) are necessary to efficiently induce an Ag-specific CD8 ϩ T-cell-mediated response. Many reports have shown that combination therapies of cancer with two therapeutic genes are more effective than a therapy with one gene. Coexpression of IL-4/granulocyte-macrophage colony-stimulating factor, 25 IL-2/IL-12, 26 IL-2/interferon-␥, 27, 28 or cytokine/ B7 29 by tumor cells or fibroblasts intensified antitumoral effects. Furthermore, the introduction of genes for both cytokines and suicide genes such as thymidine kinase or cytosine deaminase into tumor cells made the modified tumor cells sensitive to ganciclovir or 5-fluorocytosine and also activated antitumoral effector cell types by the secreted cytokines. 30, 31 The higher antitumoral efficacy of the combined cell construct may result from a combination of effector mechanisms activated by two immune-stimulating factors, IL-2 secretion and B7.1 expression. IL-2 is required for the proliferation of CTLs and enhances the activity of NK cells. 16 B7.1 molecule is a costimulatory molecule required for T-cell activation. 32 Therefore, the expression of IL-2 and B7.1 by fibroblasts is necessary for the efficient activation and proliferation of CD8 ϩ T cells. Furthermore, a high level of IL-2 in the microenvironment of Ag recognition can efficiently stimulate CTL responses and also bypass the helper of CD4 ϩ T cells in the induction of the antitumoral response. Our result showed that prior depletion of CD4 ϩ T cells before the immunization did not inhibit the induction of an anti-OVA CTL response in mice injected with the BLK/IL2/ B7.1/OVA cells (Fig 5) , consistent with earlier reports. 17 Modification of a cell line expressing defined MHC class I determinants (rather than modification of the tumor cells themselves) was investigated for two complementary reasons. First, engineered nontumorigenic APCs capable of direct priming CTLs may prove useful by allowing the manipulation of key aspects of Ag presentation, such as epitope choice, Ag density, and the selection of cytokines and costimulatory molecules, to favor the induction of potent CTL responses. In addition, fibroblasts are readily available to culture, transfect, and select and can produce physiologically relevant levels of cytokine after transfection. Furthermore, in our studies the genetically engineered cells were observed in a mouse cavity even at 2 weeks postinjection, and the cells recovered from the cavity still secreted biologically active IL-2 and/or expressed B7.1 on their surface. Furthermore, immunization with the genetically engineered BLK cells did not result in any toxicity, including high fever, weight loss, etc. Lymphoid hyperplasia or tissue necrosis was also not noted in the livers, spleens, or lungs of the mice receiving the cells (data not shown).
In conclusion, we have demonstrated that the fibroblasts can be genetically modified to efficient APCs for the induction of antitumoral CTL immunity. The efficacy of double transfectants with IL-2 and B7.1 genes is superior to single transfectants with either an IL-2 gene or a B7.1 gene.
